Gateway 2012: Metrics, Inc. - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Gateway 2012: Metrics, Inc.


Metrics, Inc.
MetricsInc.com
1240 Sugg Parkway, Greenville, NC 27834

Contact Information:
Jeff Basham, VP Sales & Marketing
jeff@metricsinc.com or 252-752-3800

Metrics Inc. is one of the most respected CDMOs in the US today. Our full range of services includes formulations development, commercial manufacturing, analytical methods development, First Time In Man, potent and cytotoxic drug handling, raw materials testing, trace metals testing and stability storage and testing.

Three critical differences set Metrics apart. One, clients work directly with a senior Metrics pharmaceutical scientist or analytical development chemist. Two, projects are expedited quickly and efficiently; they don’t languish in an analytical development queue, so timelines are met consistently. Three, Metrics’ quality assurance team is highly experienced, ensuring compliance with all regulatory issues.


Metrics is pleased to invite you to visit our booth #1119 at Interphex. To meet our team please contact Jeff Basham, VP of Sales and Marketing, at jeff@metricsinc.com or 252-752-3800.


Metrics Capabilities Brochure

Metrics Analytical Services

Metrics Potent Products

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here